Asker Healthcare Group AB (ASKER) AI Stock Analysis

• Market Cap: kr30.15B
• Dividend Yield: N/A
• Average Volume (3M): 1.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 4,238
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.55
• Shares Outstanding: 383,036,500
• 10 Day Avg. Volume: 378,678
• 30 Day Avg. Volume: 1,960,693
• PEG Ratio: 1.15
• Price to Book (P/B): 9.24
• Price to Sales (P/S): 2.13
• P/FCF Ratio: 36.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 77 Outperform
• Price Target: kr89.00 ▲(8.21% Upside)

Asker Healthcare Group AB's strong financial performance and positive technical indicators drive a favorable stock score. The lack of valuation metrics and earnings call data limits a comprehensive assessment, but the company's solid financial foundation and bullish technical signals support a positive outlook.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, enhancing the company's competitive position.

Cash Flow Generation

Strong cash flow generation supports operational needs and growth initiatives, providing financial stability and flexibility.

Operational Efficiency

Improved operational efficiency reflects better cost management and resource utilization, contributing to long-term profitability.

Negative Factors

Net Profit Margin

A low net profit margin may indicate challenges in translating revenue growth into bottom-line profitability, affecting shareholder returns.

Leverage Management

Moderate leverage with increasing debt levels can strain financial flexibility and increase risk, impacting long-term financial health.

Equity Ratio

A relatively low equity ratio may limit the company's ability to absorb financial shocks, affecting its resilience in adverse conditions.

Asker Healthcare Group AB Business Overview & Revenue Model

Company Description

Asker Healthcare Group AB provides medical supplies, devices, and equipment, and related solutions that support patient care. It offers protective products, infusion products, and dressings; measuring instruments for diabetes and blood pressure; and endoscopy equipment, incubators, and ventilators, as well as pharmaceuticals. The company also provides, supplies, and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products; and health-related protection and trauma products for emergency care, police service, and military. In addition, it offers develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; products for physiotherapy practices; supplies exercise and treatment equipment and measurement; and sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, Czech Republic, and Poland. Asker Healthcare Group AB was founded in 2018 and is based in Danderyd, Sweden.

How the Company Makes Money

ASKER generates revenue through multiple streams, primarily by selling its pharmaceutical products and medical devices to healthcare providers, hospitals, and pharmacies. The company employs a direct sales model as well as partnerships with distributors to expand its market reach. Additionally, ASKER may engage in licensing agreements for its proprietary technologies, allowing other companies to utilize its innovations in exchange for royalties or upfront fees. Strategic partnerships with research institutions and other healthcare entities also contribute to funding and collaborative development projects, enhancing ASKER's product pipeline and market presence. Overall, the combination of direct sales, licensing, and partnerships forms the backbone of ASKER's revenue model.

Asker Healthcare Group AB Financial Statement Overview

Summary

Asker Healthcare Group AB demonstrates strong financial performance with significant revenue growth and improved operational margins. The company shows robust cash flow generation, though net profitability and leverage management could be further enhanced.

Income Statement

Asker Healthcare Group AB has demonstrated strong revenue growth, with a 11.7% increase from 2023 to 2024. The gross profit margin is solid at 39.1%, and there is significant improvement in the EBIT margin to 6.4% from 4.3% in the previous year, indicating enhanced operational efficiency. The EBITDA margin also improved to 9.8%. However, the net profit margin is relatively low at 2.4%, reflecting potential non-operational costs or tax impacts.

Balance Sheet

The company's debt-to-equity ratio is 1.72, indicating moderate leverage but a slight increase in debt levels. The equity ratio of 26.4% suggests a balanced asset structure, though with room for improvement. Return on equity stands at 10.4%, which is reasonable but could be enhanced for better shareholder returns.

Cash Flow

Operating cash flow to net income ratio is robust at 3.41, suggesting strong cash generation relative to profits. There is a slight decline in free cash flow from 2023 to 2024, but the free cash flow to net income ratio remains favorable at 2.44. The overall cash flow generation is positive, supporting growth and operational needs effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.11B	15.03B	13.45B	11.72B	9.35B
Gross Profit	4.72B	5.88B	4.52B	3.78B	2.61B
EBITDA	1.17B	1.47B	1.12B	1.12B	670.00M
Net Income	362.00M	360.00M	203.00M	430.00M	467.00M
Balance Sheet
Total Assets	15.94B	13.12B	11.33B	10.23B	7.36B
Cash, Cash Equivalents and Short-Term Investments	906.00M	490.00M	391.00M	211.00M	494.00M
Total Debt	5.46B	5.96B	4.97B	4.74B	3.93B
Total Liabilities	9.43B	9.62B	8.29B	7.44B	5.54B
Stockholders Equity	6.48B	3.47B	3.02B	2.76B	1.79B
Cash Flow
Free Cash Flow	393.00M	879.00M	901.00M	853.00M	258.00M
Operating Cash Flow	760.00M	1.23B	1.05B	976.00M	382.00M
Investing Cash Flow	-2.25B	-1.46B	-783.00M	-1.86B	-843.00M
Financing Cash Flow	1.94B	305.00M	-83.00M	572.00M	619.00M

Asker Healthcare Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASKER	77 Outperform	kr30.15B	―	―	―	―	―
VITR	71 Outperform	kr18.03B	40.87	3.34%	0.80%	-1.29%	―
ARJO.B	71 Outperform	kr8.56B	19.54	5.42%	3.01%	-0.05%	-13.44%
MCOV.B	68 Neutral	kr31.95B	42.40	―	0.66%	13.89%	231.42%
ALIF.B	64 Neutral	kr18.55B	47.04	7.24%	0.46%	5.14%	236.75%
EKTA.B	55 Neutral	kr24.17B	83.02	3.08%	4.25%	-0.90%	-70.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Asker Healthcare Group AB Corporate Events

Asker Healthcare Group to Boost German Homecare Presence with GHC/MPF Acquisition

Asker Healthcare Group has agreed to acquire 100% of German Healthcare GmbH and Medicalprodukte Vertrieb Flensburg GmbH, two interlinked German homecare-focused medical supplies businesses specialising in incontinence and urology products. The target companies, which also supply clinics and pharmacies and generated around SEK 300 million in revenue with 140 employees in the past financial year, bring both global-branded items and attractive private-label ranges that Asker plans to leverage across its European network; subject to regulatory approval, the deal is expected to close in the first quarter of 2026 and to boost the group’s EBITA margin, strengthening Asker’s market position in the German homecare segment and broadening its product offering for stakeholders across Europe.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK107.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Van Heek Medical to Strengthen Benelux Presence

Asker Healthcare Group has announced the acquisition of Van Heek Medical, a prominent manufacturer and distributor of medical supplies in the Benelux region. This strategic move is expected to enhance Asker’s presence in the region and contribute positively to the company’s EBITA margin, following regulatory approvals expected in early 2026.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK107.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Announces Board Changes at Extraordinary General Meeting

At the Extraordinary General Meeting of Asker Healthcare Group AB held on December 9, 2025, the board resolved to maintain its composition of six members and approved the payment of board and committee fees to all members until the next Annual General Meeting in 2026. Karl Petersson was elected as a new board member, replacing Anders Nyman who resigned. This meeting reflects the company’s commitment to maintaining strong governance and leadership continuity, which is crucial for its ongoing operations and strategic objectives in the healthcare sector.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK107.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires French Cardiology Distributor Cardio Dépôt

Asker Healthcare Group has acquired Cardio Dépôt, a French distributor specializing in cardiology medical devices and consumables. This acquisition is expected to enhance Asker’s product offerings and digital presence in the cardiology field, positively impacting the group’s EBITA margin and supporting its growth strategy.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK107.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Interogo Holding Transfers Asker Shares to Long-Term Strategy

Interogo Holding has announced the transfer of its shares in Asker Healthcare Group from Nalka Invest to its long-term equity strategy, aligning with Asker’s recent IPO and growth trajectory. This move signifies Interogo’s commitment to Asker’s continued development, with a proposed change in the board of directors to include Karl Petersson from Interogo Long-Term Equity, ensuring stability and support for Asker’s future endeavors.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK90.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Reports Strong Q3 Growth and Strategic Expansion

Asker Healthcare Group AB reported a strong third quarter in 2025, with a 25% increase in adjusted EBITA, driven by both organic growth and strategic acquisitions. The company has expanded its footprint in the European healthcare market, including a significant entry into the French market through the acquisition of Finmed Group, enhancing its product offerings and market position.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK90.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Swiss Firm InnoMedicus AG

Asker Healthcare Group has acquired InnoMedicus AG, a Swiss distributor specializing in diagnostic devices and minimally invasive therapies for urology. This acquisition is expected to enhance Asker’s service delivery to healthcare providers and patients across Europe, particularly in prostate cancer therapies, and contribute positively to the group’s EBITA margin.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK90.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Announces Q3 2025 Webcast Presentation

Asker Healthcare Group has announced a webcast presentation for its Q3 2025 interim report, scheduled for November 6, 2025. The event will feature presentations by CEO Johan Falk and CFO Thomas Moss, followed by a Q&A session, offering stakeholders insights into the company’s recent performance and strategic direction.

The most recent analyst rating on (SE:ASKER) stock is a Hold with a SEK90.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.